Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer
The trial was a randomized, open-label, multicenter Phase II study of patients with advanced or metastatic NSCLC who don't harbor driver genes. The aim is to explore the efficacy and safety of Envafolimab Combined With Endostar/S-1 in second-line treatment of advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
DRUG: Envafolimab plus Endostar and S-1|DRUG: Envafolimab plus Endostar|DRUG: Envafolimab plus S-1
objective response rate(ORR), proportion of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors, six weeks|Adverse events, safety, three weeks
progression-free survival(PFS), the time from initial treatment to disease progression, six weeks|overall survival(OS), the time from initial treatment to death from any cause, six weeks
Patients with advanced (stage IV. NSCLC), after signing informed consent, are screened to meet the admission requirements. All the candidates are not randomly placed in 3 treatment groups (which treatment regimen the patient chooses is determined by the clinical supervisor on a patient-by-case basis).